1 August 2012 - MAP Pharmaceuticals Inc (Nasdaq: MAPP), a biopharmaceutical company focused on developing and commercialising new therapies to address patient needs in neurology, has announced today that it is planning to offer and sell shares of its common stock in an underwritten public offering.

The company aims to grant the underwriters a 30-day option to purchase an additional 15 percent of the shares of common stock to be sold in the proposed offering. All shares will be sold by the company.

The firm aims to use the funds from the proposed offering for general corporate purposes and commercialisation activities for LEVADEX(r), an orally inhaled investigational drug for the acute treatment of migraine.